Peter McSweeney is an Oncology physician affiliated with Mesoblast. OpenAlex indexes 238 publications with 24,381 citations (h-index 61); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1721 E 19th Ave Ste 300
Denver, CO 802181258
Telephone
720-754-4800Registry record last updated 22 Jun 2016.
Clinical trials
- SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
Sponsor: Colorado Blood Cancer Institute
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Sponsor: Colorado Blood Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- Mesoblast, Inc.Program year20251 payment
- ABBVIE INC.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine
2021 - Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
British Journal of Haematology
2021 - KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
New England Journal of Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”